Effects of RAAS Inhibitors in Patients with Kidney Disease
- 935 Downloads
Proteinuria and decline of renal function are associated with progression of kidney disease. The Renin Angiotensin Aldosterone System (RAAS) plays an important role in blood pressure regulation, fluid volume, and sodium balance. Overactivity of RAAS contributes to the pathogenesis of a variety of clinical conditions including progress of chronic kidney disease (CKD). This review summarizes the use of RAAS inhibitors as dual therapy or monotherapy in different stages of kidney disease. Experimental and clinical studies have demonstrated RAAS inhibitors prevent proteinuria, kidney fibrosis and slow decline of renal function and thus play a protective role in both early and end stages of kidney disease. While combination use of RAAS inhibitors showed higher efficiency compared with monotherapy, it is also associated with higher incidence of adverse events. Besides ACEI/ARBs, more mechanism research of mineralocorticoid receptor antagonists in kidney disease should be performed.
KeywordsRenin Angiotensin Aldosterone System RAAS RAAS inhibitors Chronic kidney disease Proteinuria
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.•• Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486–92. The "aldosterone escape phenomenon” which is the basis of a combination of RAAS inhibitors and residual renal function, protected with RAAS inhibitors, plays an important role in preservation of survival and quality of life of ESRD patients.CrossRefPubMedGoogle Scholar
- 12.Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56(4):714–9.CrossRefPubMedGoogle Scholar
- 22.•• Brener ZZ, Kotanko P, Thijssen S, Winchester JF, Bergman M. Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians. Am J Med Sci. 2010;339(5):453–6. The "aldosterone escape phenomenon” which is the base of combination of RAAS inhibitors and residual renal fucntion, protected with RAAS inhibitors, plays an important role in preservation of survival and quality of life of ESRD patients.CrossRefPubMedGoogle Scholar
- 25.• Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11(3):556–64. This demonstrated that ACEI/ARB has a beneficial effect on RRF of ESRD patients and possible mechanisms. PubMedGoogle Scholar
- 35.Mummidi S, Das NA, Carpenter AJ, Kandikattu H, Krenz M, Siebenlist U, et al. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol. 2016;98:95–102.CrossRefPubMedGoogle Scholar